Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma.

Autor: Guzmán-Casta J; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Carrasco-CaraChards S; Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico., Guzmán-Huesca J; Internal Medicine, Bonita Community Health Center, Florida EE.UU., Bonita Springs, Florida, USA., Sánchez-Ríos CP; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Riera-Sala R; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Martínez-Herrera JF; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Peña-Mirabal ES; Department of Pathology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Bonilla-Molina D; Department of Internal Medicine, Ciudad de México, Hopital Ángeles Lomas, Mexico., Alatorre-Alexander JA; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Martínez-Barrera LM; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico., Rodríguez-Cid JR; Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico.
Jazyk: angličtina
Zdroj: Thoracic cancer [Thorac Cancer] 2021 Apr; Vol. 12 (7), pp. 1014-1022. Date of Electronic Publication: 2021 Mar 04.
DOI: 10.1111/1759-7714.13814
Abstrakt: Background: Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced disease at the time of presentation. Exposure to asbestos is the most important risk factor for malignant pleural mesothelioma. Mesothelioma is a neoplasia with a long preclinical stage that can span from 15 to 40 years.
Methods: This was a descriptive, observational, retrospective study of 136 patients with a confirmed diagnosis of mesothelioma, which compared histological subtypes, immunohistochemical biomarkers, concomitant chronic degenerative diseases, tobacco use, age at the time of diagnosis, clinical stage and chemotherapy agents used or other treatments such as radiotherapy and surgery to identify all the factors that impact in the prognosis of overall survival (OS) and progression-free survival (PFS).
Results: A total of 136 patients were included in the study. In the total study population, 84 patients were male (61.8%) and 52 were female (38.2%). Median PFS was nine months (95% confidence interval [CI]: 8.4-9.5 months) and median OS was 12 months (95% CI: 11.3-12.6). The results indicated that the most determining prognostic factors for OS and PFS were cell differentiation measured by immunohistochemical biomarkers, the treatment chosen, and that RECIST was the most significant in the evaluation of patient response to treatment.
Conclusions: Malignant pleural mesothelioma is a cancer with a poor prognosis usually diagnosed at an advanced stage of disease. Our study revealed that the prognostic factors for OS and PS were cell differentiation, the treatment chosen and RECIST.
(© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: